Regeneron Pharmaceuticals (STU:RGO) Short Interest


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
85 GF Score
Price €554.60
GF Value €788.02
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:RGO vs ALNY, RVMD, ONC: Short Interest Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Short Interest falls into.


STU:RGO
85GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €554.60 is trading 29.6% below its estimated GF Value™ of €788.02. GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:RGO:

  • Short Interest:
  • GF Value™: €788.02 vs. price of €554.60 (29.6% below fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
85GF Score

Get the complete analysis for STU:RGO

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€554.60
Price
€788.02
GF Value